Show simple item record

dc.contributor.authorRobles-Zurita, Jen_US
dc.contributor.authorBoyd, KAen_US
dc.contributor.authorBriggs, AHen_US
dc.contributor.authorIveson, Ten_US
dc.contributor.authorKerr, RSen_US
dc.contributor.authorSaunders, MPen_US
dc.contributor.authorCassidy, Jen_US
dc.contributor.authorHollander, NHen_US
dc.contributor.authorTabernero, Jen_US
dc.contributor.authorSegelov, Een_US
dc.contributor.authorGlimelius, Ben_US
dc.contributor.authorHarkin, Aen_US
dc.contributor.authorAllan, Ken_US
dc.contributor.authorMcQueen, Jen_US
dc.contributor.authorPearson, Sen_US
dc.contributor.authorWaterston, Aen_US
dc.contributor.authorMedley, Len_US
dc.contributor.authorWilson, Cen_US
dc.contributor.authorEllis, Ren_US
dc.contributor.authorEssapen, Sen_US
dc.contributor.authorDhadda, ASen_US
dc.contributor.authorHughes, Ren_US
dc.contributor.authorFalk, Sen_US
dc.contributor.authorRaouf, Sen_US
dc.contributor.authorRees, Cen_US
dc.contributor.authorOlesen, RKen_US
dc.contributor.authorPropper, Den_US
dc.contributor.authorBridgewater, Jen_US
dc.contributor.authorAzzabi, Aen_US
dc.contributor.authorFarrugia, Den_US
dc.contributor.authorWebb, Aen_US
dc.contributor.authorCunningham, Den_US
dc.contributor.authorHickish, Ten_US
dc.contributor.authorWeaver, Aen_US
dc.contributor.authorGollins, Sen_US
dc.contributor.authorWasan, HSen_US
dc.contributor.authorPaul, Jen_US
dc.identifier.citationBr J Cancer, 2018, 119 (11), pp. 1332 - 1338en_US
dc.description.abstractBACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. METHODS: In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken. RESULTS: The 3 M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3 M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3 M had lower QALYs than 6 M (not statistically significant). CONCLUSIONS: Overall, 3 M dominates 6 M with no significant detrimental impact on QALYs. The results provide the economic case that a 3 M treatment strategy should be considered a new standard of care.en_US
dc.format.extent1332 - 1338en_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectChemotherapy, Adjuvanten_US
dc.subjectColorectal Neoplasmsen_US
dc.subjectCost-Benefit Analysisen_US
dc.subjectQuality of Lifeen_US
dc.subjectQuality-Adjusted Life Yearsen_US
dc.subjectSurvival Analysisen_US
dc.titleSCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.en_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBr J Canceren_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden_US

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as